Tumor Blood Vessels

New vascular targeting agents win patent

Published in Cancer Weekly, November 26th, 2002

Peregrine Pharmaceuticals (PPHM) announced the issuance of U.S. Patent No. 6,451,312 covering new vascular targeting agent (VTA) therapeutics.

Peregrine's VTA technology is based on targeting agents that specifically target tumor blood vessels.

The targeting agents can be attached to therapeutic agents that destroy or occlude tumor blood vessels, leading to an avalanche of tumor cell death without harming the vasculature of normal tissue.

The new patent extends the company's broad patent coverage of VTA compositions and treatment methods by providing a unique "targeting agent- therapeutic agent" combination. The targeting agent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-11-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry